Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.

Article Details

Citation

Copy to clipboard

Yuan Z, Tam VH

Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.

Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661 .

PubMed ID

18447592 [ View in PubMed

]

Abstract

BACKGROUND: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent. OBJECTIVE: To review what is known about polymyxin B and to identify missing information or gaps for future investigations. METHODS: Pertinent information was reviewed from published literature in English. RESULTS/CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Polymyxin B	Bacterial outer membrane	Group	Bacteria	Yes	Incorporation into and destabilization	Details